Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
The Food and Drug Administration (FDA) is amending its investigational new drug application (IND) regulations to clarify that, within 30 days after the receipt of an IND for any clinical investigation involving an exception from informed consent, FDA will provide a written determination as to whether the investigation may begin. This action is intended to clarify a recent amendment to the IND regulations for clinical investigations involving an exception from informed consent that states that FDA will provide a written authorization within 30 days of receipt of the IND.
D015507:Drugs, Investigational; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence*; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration